News

Xconomy: Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
Xconomy National— A week after the failure of Biogen’s Alzheimer’s drug aducanumab, the ripple effects are still being felt—and not just by Biogen, which lost billions of dollars in market value in a flash. We’ll kick off this week’s roundup with the aducanumab reaction, which includes plenty of thoughts about the future of the so-called […] » Read more
ENDPOINTS: Three biotechs raise $100M+ in funding for gene therapies, cancer vaccines and more
– Another day, another gene therapy developer. Prevail Therapeutics, which leapt out of stealth mode in 2017 and raised $75 million in a Series A last year for its disease-modifying approach to neurode generative diseases, has secured another $5o million in the bank. The New York-based company is run by Columbia University’s Asa Abeliovich, who […] » Read more
FierceBiotech: Elicio Therapeutics aims to sneak cancer vaccines into the lymph nodes, with $30M to launch
by Conor Hale – By targeting the body’s lymph nodes with anti-cancer vaccines, new immunotherapy developer Elicio Therapeutics aims to focus on ground zero of the body’s immune system. And to do it, the startup is getting underway with $30 million in funds, a new CEO and tech from the Massachusetts Institute of Technology. Elicio […] » Read more
BioCentury: Elicio raises $30m to target cancer vaccines to the lymph nodes
by Mary Romeo, Staff Writer – Elicio launched Wednesday with $30 million in funding and an immunotherapy strategy aimed at getting cancer vaccines into the lymph nodes, a location that orchestrates immune responses but has been hard to target directly. Elicio Therapeutics (Cambridge, Mass.) has exclusively licensed the Amphiphile platform from Darrell Irvine at the […] » Read more
Immuno-Oncology Company Elicio Therapeutics Launches with Novel Vaccine & Immunotherapy Platform to Treat an Array of Cancers
$30 Million Financing Backing MIT-Developed Amphiphile Platform to Target a Wide-Range of Immunogens to the Lymph Nodes, the “Brain Center’ of the Immune Response CAMBRIDGE MA., March 27, 2019 (BusinessWire) – Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, launched today and announced the appointment of Robert Connelly as […] » Read more